Skip to Content
Global News Select

Chengdu Quanyuantang Pharmacy Plans Hong Kong IPO

   By Ben Otto 
 

Chengdu Quanyuantang Pharmacy Chain Joint Stock Co. is planning an initial public offering in Hong Kong, part of efforts to expand its pharmacy business in China.

The pharmacy operator, which counts Sino Biopharmaceutical Ltd. and a unit of options-trading giant Susquehanna International Group as shareholders, said it will also use proceeds to boost technological capacity and make acquisitions and investments.

It didn't specify a timeline for the offering nor say how much it intends to raise.

Chengdu Quanyuantang Pharmacy, founded in 2012, runs 369 pharmacies across 13 cities in China, in addition to 38 online stores on e-commerce platforms such as JD.com.

It posted revenue of 1.25 billion yuan (US$195.7 million) in 2020, up from CNY858.2 million in 2019 and CNY576.5 million in 2018, according to the filing. It attributed losses in each of those years to efforts to expand its pharmacy network.

Citigroup and Haitong International Capital are acting as joint sponsors for the offering.

 

Write to Ben Otto at ben.otto@wsj.com

 

(END) Dow Jones Newswires

June 09, 2021 22:34 ET (02:34 GMT)

Copyright (c) 2021 Dow Jones & Company, Inc.

Transparency is how we protect the integrity of our work and keep empowering investors to achieve their goals and dreams. And we have unwavering standards for how we keep that integrity intact, from our research and data to our policies on content and your personal data.

We’d like to share more about how we work and what drives our day-to-day business.

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions. Our investment management business generates asset-based fees, which are calculated as a percentage of assets under management. We also sell both admissions and sponsorship packages for our investment conferences and advertising on our websites and newsletters.

How we use your information depends on the product and service that you use and your relationship with us. We may use it to:

  • Verify your identity, personalize the content you receive, or create and administer your account.
  • Provide specific products and services to you, such as portfolio management or data aggregation.
  • Develop and improve features of our offerings.
  • Gear advertisements and other marketing efforts towards your interests.

To learn more about how we handle and protect your data, visit our privacy center.

Maintaining independence and editorial freedom is essential to our mission of empowering investor success. We provide a platform for our authors to report on investments fairly, accurately, and from the investor’s point of view. We also respect individual opinions––they represent the unvarnished thinking of our people and exacting analysis of our research processes. Our authors can publish views that we may or may not agree with, but they show their work, distinguish facts from opinions, and make sure their analysis is clear and in no way misleading or deceptive.

To further protect the integrity of our editorial content, we keep a strict separation between our sales teams and authors to remove any pressure or influence on our analyses and research.

Read our editorial policy to learn more about our process.